Unity Biotechnology, Inc. - Common Stock (UBX)

The healthcare industry stands on the brink of a transformative decade, driven by rapid advancements in technology, shifting demographics, and evolving patient expectations. Over the next ten years, we will witness groundbreaking changes that redefine how care is delivered, diseases are treated, and wellness is maintained. Below, we explore ten

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.

Traders are paying attention to the gapping stocks in Monday's session. Let's dive into which stocks are experiencing notable gaps.

Unity diabetes study showing durable vision gains with full 36-week data expected in Q2 2025.

Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

UBX stock results show that Unity Biotechnology beat analyst estimates for earnings per share the first quarter of 2024.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

UBX stock results show that Unity Biotechnology beat analyst estimates for earnings per share the fourth quarter of 2023.

Wedbush analyst Andreas Argyrides upgraded the shares of Unity Biotechnology Inc (NASDAQ: UBX) from Neutral to Outperform and

Here are the best longevity stocks to consider. Each stock listed comes with their unique reasons to buy them.